Purpose of review Colistin is a 50-year-old antibiotic that is being used increasingly as a 'last-line' therapy to treat infections caused by multidrug-resistant Gram-negative bacteria, when essentially no other options are available. Despite its age, or because of its age, there has been a dearth of knowledge on its pharmacological and microbiological properties. This review focuses on recent studies aimed at optimizing the clinical use of this old antibiotic.
Introduction
Colistin (also known as polymyxin E) has been marketed as its inactive prodrug colistin methanesulfonate (CMS) [1] for 50 years. Colistin was one of the first antibiotics with significant activity against Gramnegative bacteria, notably Pseudomonas aeruginosa. It exhibits rapid, concentration-dependent bactericidal activity [2, 3, 4 ] . CMS was largely replaced by aminoglycosides in the 1970s because of concern about nephrotoxicity and neurotoxicity [5,6,7 ,8 ] . In the past 10-15 years, however, CMS/colistin has been a limited option and used as 'salvage' therapy for infections caused by multidrug-resistant (MDR) Gram-negative bacteria, in particular P. aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae [5,6,7 ,8 ] . The lack of alternative antibiotics has been exacerbated by the dry antimicrobial drug development pipeline [9] . Having entered clinical use in 1959, CMS/colistin was never subjected to drug development procedures that are now mandated by international drug regulatory agencies such as the Food and Drug Administration (FDA). As a result, there is a dearth of pharmacological information informing rational use, which aims to maximize antibacterial activity while minimizing toxicity and development of resistance [5, 8 ] . There are no scientifically based dosage regimens for various categories of patients, in particular people with cystic fibrosis (CF) and subsets of critically ill patients (e.g. with differing levels of renal function, including those on renal replacement therapy). Even though rates of colistin resistance have been relatively low, probably because of its infrequent use, there have recently been several outbreaks of infections caused by colistin-resistant bacteria [10,11,12 ,13] . As no novel antibiotics with activity against Gram-negative bacteria will be available within the next 9-11 years [14] , there is an urgent need to optimize use of CMS/colistin. Background information on colistin is summarized in recent extensive reviews [5,6,7 ,8 ] . The present review will focus on recent advances in colistin pharmacology, clinical use and ongoing dilemmas.
Do we know how to optimize dosing of colistin?
The simple answer to the abovementioned question is 'No'. In part this is due to inconsistent labeling and different dosing regimens recommended for different pharmaceutical products [8 ,15,16,17 ] ). Some product labels express the content of CMS as international units (IU; there are $12 500 IU/mg of CMS). Other products are labeled with 'colistin base activity' (based upon microbiological standardization), even though the material contained in the vials is CMS. For products labeled in international units, the manufacturer-recommended dose for a patient with normal renal function who is over 60 kg is 1-2 million IU three times daily (to a maximum of 6 million IU per day), equivalent to 240-480 mg of actual CMS per day. In contrast, for products labeled with 'colistin base activity', the manufacturer-recommended dose ranges from 2.5 to 5 mg/kg of 'colistin base activity' per day, in two to four divided doses; this is equivalent to approximately 6.67-13.3 mg/kg of actual CMS per day. Hence, for a person with normal renal function and body weight of 60 kg, the recommended daily dose of this type of product is 400-800 mg of CMS. Although this disparity in labeling and manufacturer-recommended daily doses was identified 2-3 years ago and an urgent call made for international harmonization [8 ,15,18] , the problem is unresolved and is arguably worse because of the proliferation of generic brands of parenteral CMS formulations. There are two important implications of the differences. First, for those clinicians referring to published reports of studies involving CMS/colistin to guide their practice, insufficient detail is often provided in published papers to ascertain the doses of CMS actually used. Confusion regarding this is illustrated in a recent review [19] of intraventricular CMS for treatment of A. baumannii ventriculitis, in which doses of CMS were tabulated in milligrams, but for a product labeled with 'colistin base activity' [20] it was not clear whether the milligrams of 'colistin base activity' had been converted to milligrams of CMS. The second unresolved issue is the most appropriate daily dose. However, in an era in which CMS/colistin is being used increasingly as 'salvage' therapy for infections that are resistant to most other antibiotics, it is clearly important to administer doses that maximize antibacterial effect and minimize the potential for development of resistance. As acceptable and similar safety appears to exist for both types of products [21] [22] [23] [24] [25] [26] [27] , at this time, it would be prudent to regard the daily dose of the products labeled with 'colistin base activity' as a 'reasonable' choice [i.e. 2.5-5 mg/kg of 'colistin base activity' per day (corresponding to $400-800 mg CMS per day) in a 60 kg patient with normal renal function]. In fact, despite manufacturer's recommendations not to exceed 6 million units per day, some clinicians [28, 29] are now routinely using an upper daily dose of 9 million IU per day (corresponding to $720 mg CMS per day). Clearly, studies must be done to resolve the dosage issue. Furthermore, the number of doses per day suggested for patients with normal kidney function is 2-4, though twice-daily or thrice-daily dosing appears to be the most commonly used [6,7 ,8 ] . In the absence of supporting pharmacokinetic/pharmacodynamic data, some have used once-daily dosing, even in patients with normal kidney function [26] . We recommend against this practice. In an in-vitro pharmacokinetic/pharmacodynamic model that simulated human dosing regimens incorporating higher doses of colistin administered once daily, there was greater emergence of resistance in P. aeruginosa than occurred with a thrice-daily regimen involving administration of essentially the same total daily dose [30] . Moreover, intravenous administration of CMS to rats in week-long multiple-dose regimens mimicking twice-daily and once-daily administration of a clinically relevant human daily dose resulted in a greater range and severity of renal lesions with the oncedaily dosing equivalent. This suggests that the potential for nephrotoxicity may be greater with extended-interval dosing [31] . In support of this, in-vitro studies have shown that the effect of toxicity of colistin on mammalian cells is concentration-dependent and time-dependent [32] .
Until the last few years, little has been known of the pharmacokinetics and pharmacodynamics and, importantly, the relationship between the pharmacokinetics and pharmacodynamics for CMS/colistin. A recent study conducted on a standard mouse thigh infection model [33] revealed that the ratio of the area under the plasma concentration-time curve to the minimum inhibitory concentration (MIC) (AUC/MIC) is the most predictive index of activity against P. aeruginosa [34] ; a study conducted on the same model against the same microorganism, but without measurement of pharmacokinetic behavior, suggested that activity may be correlated with the ratio of the maximum plasma concentration to MIC (C max /MIC) [35] . There is evidence that the protein binding of polymyxins may be different in the plasma of infected patients (and animals), possibly related to infectioninduced changes in the plasma concentration of a 1 -acid glycoprotein, an acute-phase reactant that is important for the binding of many basic drugs [36, 37] and whose concentration is higher in critically ill patients [38] . The ability to translate pharmacokinetic/pharmacodynamic targets, based upon total plasma concentration, determined in animal models or in humans, to assist in optimizing dosing strategies for patients requires a more complete understanding of the plasma protein binding of colistin.
Different pharmacokinetics in various patient groups clearly have potential to impact the dosage regimens required to treat infections. There is emerging evidence that the pharmacokinetics of CMS/colistin differs in the key groups, namely, people with CF [25, 39, 40] and critically ill patients ( [41,42 ,43,44] , unpublished data).
For example, the half-life of the active antibacterial colistin formed in vivo from its prodrug, CMS, is about 4 h in CF patients [25, 39, 40] but is longer in critically ill patients ( [41,42 ,43,44] , unpublished data). A recently reported population pharmacokinetic study, though with a small number of patients (n ¼ 18), provided useful new insights into the disposition of CMS and formed colistin in critically ill patients [42 ] . Patients received CMS intravenously (as a 15-min infusion) at a dose of 3 million IU (equivalent to $240 mg CMS) every 8 h; the dose was reduced empirically to 2 million IU ($160 mg CMS) every 8 h in two patients with a creatinine clearance less than 50 ml/min. Mean creatinine clearance was 82.3 ml/ min (range 41-126 ml/min) and none of the patients required renal replacement therapy. CMS and colistin plasma levels were measured after the first and fourth doses. The predicted C max of formed colistin (0.60 mg/l) after the first dose was substantially lower than that at steady state (2.3 mg/l after the fourth dose) because of a slow rate of formation of colistin from CMS and accumulation of formed colistin over the first several doses, in keeping with its estimated half-life of 14.4 h. The plasma binding of colistin was not considered in this study. Even so, the plasma concentrations of colistin, which was administered at a daily dose 50% higher than that recommended by the manufacturer, were well below (first dose) or modestly above (fourth dose) the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC breakpoint (2 mg/l) for P. aeruginosa and A. baumannii. This prompted the authors to question the appropriateness of the current dosage regimens. In view of the delay in attainment of plasma colistin concentrations in this study [42 ] and the known importance of initiating appropriate antimicrobial therapy as quickly as possible [45] , the authors also suggested that it may be advantageous to administer a loading dose of CMS (e.g. 9 million IU, equivalent to $720 mg CMS) with a maintenance dose of 4.5 million IU (equivalent to $360 mg CMS) every 12 h [42 ] , though such regimens remain to be tested clinically. This study [42 ] highlights the need for a large population pharmacokinetic study, incorporating pharmacodynamic endpoints (e.g. bacterial eradication, clinical cure, development of resistance) together with toxicodynamic endpoints (e.g. nephrotoxicity) and involving patients with a wider range of renal function (including those requiring renal replacement therapy) and other comorbidities. A National Institute of Health (NIH)-funded project (grant number 5R01AI070896-02) that addresses these requirements in various categories of critically ill patients is currently underway.
Current clinical uses of colistin
The resurgence in the use of CMS/colistin began in the late 1980s and early 1990s, when it was administered intravenously and/or by inhalation to manage infections or colonization with P. aeruginosa in pediatric and adult patients with CF. In the last decade, it has been used to treat a range of infections [e.g. ventilator-associated pneumonia (VAP), bacteremia] caused by MDR Gramnegative bacteria, in particular P. aeruginosa, A. baumannii and K. pneumoniae, in critically ill adult patients; most typically, it is administered intravenously. Although generally considered to be efficacious and well tolerated in this setting [6, 8 ] , there is a paucity of randomized controlled trials; many studies are retrospective in nature and other antibiotics are often used in combination (e.g. [6,8 ,46] ). In addition, small sample sizes and resultant lack of power substantially compromise the usefulness of many studies; for example, a recent prospective cohort study on adult critically ill patients intended to compare high-dose ampicillin/sulbactam versus CMS intravenous monotherapy for treatment of MDR A. baumannii VAP had a power of 6% [47] .
Inhalation of CMS has been used in CF over the last two decades and in Greece is now being used in critically ill and ICU patients for treatment of VAP [48, 49] . The rationale is appealing: delivery of antibiotic directly to the infection site with the intention of achieving selective targeting (i.e. effective concentrations in lung fluid, while minimizing systemic exposure and potential adverse effects such as nephrotoxicity) [50] . Aerosolized CMS [2.2 AE 0.7 million IU per day (equivalent to $176 AE 56 mg CMS per day), for a mean duration of 16.4 days] was examined prospectively in 60 critically ill patients requiring treatment for VAP caused by MDR P. aeruginosa, A. baumannii or K. pneumoniae. Bacteriological and clinical response of VAP was observed in 83.3% of patients; no adverse effects were recorded and all-cause hospital mortality was 25% [49] . It should be noted that all but three of the 60 patients received concomitant intravenous treatment with CMS or other antibiotics. In a retrospective case series (five patients), the same group examined inhaled CMS as 'monotherapy' (meaning no concurrent intravenous CMS) for treatment of nosocomial pneumonia caused by P. aeruginosa, A. baumannii and/or K. pneumoniae [48] . Although no intravenous CMS was administered, patients did receive other intravenous antibiotics (to which the isolated pathogens were resistant). Although it was concluded from these studies that inhaled CMS may be well tolerated and effective for treatment of VAP [48, 49] , the confounding influences (e.g. concomitant administration of intravenous CMS or other antibiotics), small sample sizes and lack of control groups complicate interpretation of the data. Other factors that require consideration are the appropriateness of the inhaled dose (i.e. dose-ranging studies are required) and pharmaceutical formulation (e.g. does the current inhalational formulation, which is largely based upon the parenteral formulation, maximize delivery of appropriately sized droplets to the airways?). In addition, Colistin in the 21st century Nation and Li 537 the conversion of CMS to colistin within the lung fluid would be a prerequisite for antibacterial activity, but there is no information regarding this or indeed other aspects of the disposition of CMS and colistin following pulmonary administration (e.g. effective half-life in lung fluid, absolute systemic bioavailability).
Inhalational administration of CMS is not approved by the FDA [51] but, as discussed above, is common in CF clinics throughout the world and increasingly so in some ICUs [52] [53] [54] . Recently, the purported formation of colistin in a solution of CMS (reconstituted from the CMS parenteral formulation, Coly-Mycin M) was implicated in the death of a patient with CF following inhalation [55] and this led to the issuing of an FDA Alert (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm118080. htm). Unfortunately, virtually no information relating to the death has been made publicly available (e.g. the concentration of CMS in the solution and the transportation and storage conditions for the solution). However, a stability study conducted on a CMS Solution for Inhalation (77.5 mg CMS per ml) specially prepared by a hospital pharmacy department found that the conversion of CMS to colistin was highly concentration-dependent; less than 0.1% colistin was formed over a 1-year period when the CMS Solution for Inhalation was stored at either 4 or 258C [17 ]. Despite the low level of colistin observed in that study, it is prudent to reconstitute lyophilized CMS as close as possible prior to administration by inhalation (or parenteral injection) to minimize the potential for in-vitro formation of colistin in these CMS dosing solutions [17 ]. As noted above, colistin is formed in vivo after inhalational [56] or intravenous [39,41,42 ,44] administration of CMS.
The intrathecal or intraventricular administration of CMS to treat central nervous system (CNS) infections has been reviewed previously [6,8 ,57] and reports continue to accumulate [19, 58] . Administration via these routes is usually instituted when there is concern whether intravenous CMS will adequately penetrate into the site of infection or when intravenous administration has actually been shown to be ineffective. Recently, it has been suggested that intraventricular administration of CMS is effective for the treatment of ventriculitis caused by MDR A. baumannii [19, 58] . It is interesting that this treatment appears to be remarkably well tolerated, though chemical ventriculitis, chemical meningitis and seizures have been reported in some patients [19] . Clearly, the potential for publication bias needs to be kept in mind when considering the apparent efficacy and safety of this form of treatment.
Although CMS/colistin has been used in pediatric patients with CF for decades, only recently has it been used outside this group, as an important last-line antibiotic for treatment of MDR Gram-negative infections [59, 60 ] .
Potential for nephrotoxicity and neurotoxicity
Nephrotoxicity and neurotoxicity are the most common adverse effects of intravenous administration of CMS. Neurotoxicity is rare [6,8 ,22,61,62 ] . Nephrotoxicity is more common and is of most concern to prescribing clinicians. A recent retrospective cohort study [22] comparing the safety and efficacy of CMS/colistin and tobramycin for treatment of MDR A. baumannii infections in ICU patients found that the risks of nephrotoxicity were similar. The authors acknowledged a number of limitations of this small study [22] .
A retrospective study conducted at the Walter Reed Army Medical Center involving personnel injured in Iraq and Afghanistan assessed the incidence of nephrotoxicity associated with intravenous administration of CMS [63 ] . In that study, the majority of patients were young and previously healthy, without underlying risk factors for kidney dysfunction. CMS was administered intravenously in a mean (AESD) dose of 4.3 AE 1.2 mg/kg/day of 'colistin base activity' (equivalent to $11.5 AE 3.2 mg CMS/kg/day) for 15.8 AE 9.2 days. The authors used the well validated RIFLE system of criteria (risk, injury, failure, loss and end-stage kidney disease [64 ] ) to categorize acute kidney injury (AKI, as opposed to acute renal failure) from mild renal dysfunction to the need for renal replacement therapy. The incidence of AKI (categorized at the R, I or F level as defined by RIFLE) while receiving CMS at the time of the peak serum creatinine was 45% in the 66 patients who met inclusion criteria (!18 years, received intravenous CMS for >72 h and not on renal replacement therapy prior to the initiation of CMS). No patient was categorized at the L or E level of RIFLE at the time of the peak serum creatinine and no patient required renal replacement therapy, despite the fact that several had evidence of acute tubular necrosis on urine microscopy. Patients who received CMS for more than 14 days had a 3.7-fold increased risk of nephrotoxicity. This risk did not appear to be related to daily dose of CMS, but rather the total cumulative dose. This indicates the need to carefully monitor kidney function in patients requiring prolonged therapy with CMS [63 ] and to avoid prolonged treatment courses, whenever possible. Importantly, at 1 month after cessation of CMS, serum creatinine concentrations had returned to baseline, with a mean (AESD) difference of 0.04 AE 0.3 mg/dl (P ¼ 0.34).
It is important to place in perspective the potential for nephrotoxicity caused by CMS/colistin. First, the overwhelming evidence from studies reviewed previously [6,7 ,8 ] and from the recent Walter Reed study [63 ] reveals that renal injury caused by CMS/colistin is relatively mild and almost always reversible over weeks to months after ceasing therapy. Second, CMS/colistin is not the only antibiotic that is potentially nephrotoxic. Interestingly, in relatively recent studies conducted on people with CF, the potential for nephrotoxicity from CMS/ colistin compared favorably with that from the aminoglycosides [65, 66] . Finally, as with many other areas of patient management, risk : benefit must be considered. The use of CMS/colistin to treat a life-threatening infection caused by a Gram-negative pathogen that is resistant to virtually every other currently available antibiotic must be weighed against the potential for drug-induced mild, reversible kidney injury.
Mechanisms of antibacterial activity and resistance
The bactericidal effect of colistin is extremely rapid, but there is limited knowledge of the mechanism of antibacterial activity. As there is only one amino acid difference between colistin and polymyxin B, it is believed that they have the same mechanism of action [8 ] . Polymyxin B interacts with the lipopolysaccharide (LPS) of the outer membrane of Gram-negative bacteria and competitively displaces divalent cations (Ca 2þ and Mg 2þ ) from the negatively charged phosphate groups of the lipid A of LPS [6,7 ,8 ,67,68] . Both the positively charged amine groups and the hydrophobic fatty acyl chain of polymyxin B play important roles in the interaction with bacterial LPS [5,8 ,67,68] . Hancock [68] presented a self-promoted uptake model to explain the antibacterial mechanism of cationic peptides.
Currently, resistance to colistin is relatively rare, probably due to its low usage over the past 50 years [69] . However, polymyxin-resistant bacteria have been identified [10,11, 12 ,13] and several molecular mechanisms of resistance have been characterized in Gram-negative pathogens. The most common mechanisms of resistance to colistin are modifications to LPS, the initial site of action of colistin. In Escherichia coli [70, 71] , Salmonella enterica serovar typhimurium [72] , K. pneumoniae [73] and P. aeruginosa [74] , net LPS negative charge is reduced due to the modification of the lipid A with 4-amino-4deoxy-L-arabinose (L-Ara4N) and/or phosphoethanolamine (PEtn). A recent study indicated that resistance to colistin in A. baumannii is associated with mutations in the PmrAB two-component system [75] ; however, modification of lipid A was not examined in that study. In Burkholderia cenocepacia, the LPS O-antigen or inner core sugars act to shield the lipid A negative charge and two UDP-glucose dehydrogenases contribute to the viability and polymyxin B resistance [76] . The presence of capsule is critical for polymyxin resistance in K. pneumoniae [77, 78] and Neisseria meningitides [79] . In addition, toler-ance to colistin in P. aeruginosa biofilms is linked to metabolically active cells and controlled by the pmr and mexAB-oprM genes [80] .
Although the mechanisms of resistance to colistin are still to be fully elucidated, there are signs of increasing rates of resistance in clinical isolates [10,11,12 ,13] . A recent investigation of risk factors for isolation of colistin-resistant bacteria identified, from a multivariate statistical model used to explore possible covariates, that CMS/ colistin use was the only independent risk factor [81 ] . This highlights the importance of using CMS/colistin judiciously and optimizing its dosage regimens based on yet to be completed population pharmacokinetic, pharmacodynamic and toxicodynamic studies.
Combination therapy with colistin
Considering the increasing resistance to colistin, systematic examination of the potential for synergy between colistin and other antibiotics is warranted. A limited number of clinical studies have prospectively evaluated the efficacy of combinations of CMS/colistin with other antibiotics. The majority have been conducted in vitro, in animal infection models or involve retrospective clinical studies. This review focuses on the studies on the combinations with CMS/colistin since 2008. For previous studies, please refer to recent reviews [8 ,82 ] .
The majority of the in-vitro studies on combinations with colistin examined, using chequerboard or static time-kill methods, rifampicin, imipenem, meropenem, ciprofloxacin, gentamicin, ceftazidime, doxycycline, minocycline, azithromycin, piperacillin and cotrimoxazole against P. aeruginosa, A. baumannii and K. pneumoniae [82 ] . Although rifampicin is the most commonly studied antibiotic in combination with colistin, carbapenems have been extensively examined in the past 2 years. Souli et al. [83] reported that the combination of colistin and imipenem was synergistic (50% of isolates) or indifferent (50%) against colistin-susceptible blaVIM-1-type metallo-b-lactamase-producing (MBL) K. pneumoniae strains, whereas it was antagonistic (55.6%) and rarely synergistic (11%) against colistin-resistant strains. Interestingly, after 24-h exposure to the tested combination, resistance to colistin (MICs 64-256 mg/l) was observed in seven of 12 isolates that were initially susceptible to colistin. In contrast, among four isolates initially susceptible to imipenem that showed regrowth at 24 h in the presence of the combination, none developed resistance to imipenem [83] . In another study, subinhibitory concentrations of meropenem (0.06-8 mg/l) and colistin (0.12-1 mg/l) showed synergy against 13 out of 51 P. aeruginosa isolates at 24 h, whereas the combinations of meropenem (0.03-64 mg/l) and colistin (0.06-8 mg/l) showed synergy against 49 A. baumannii isolates [84] .
Using static time-kill methods, synergy was shown with meropenem (1Â MIC) and polymyxin B (0.25, 0.5 and 1Â MIC) against eight genetically unique meropenemresistant (MICs !24 mg/l) A. baumannii isolates [85] . Although synergy was observed with the combination of colistin and tigecycline against MDR A. baumannii isolates using chequerboard methods, time-kill studies did not confirm the synergy [86, 87] . Caution is required when interpreting fractional inhibitory concentrations of antibiotic combinations, including those with colistin. Recently, the phenomenon of colistin heteroresistance has been reported in A. baumannii clinical isolates [88,89,90 ,91] . Colistin heteroresistance is the existence of colistin-resistant subpopulations within an isolate that is susceptible based upon MIC. The proportion of colistin-heteroresistant isolates was significantly higher among those collected from patients treated with colistin [91] . When colistin-heteroresistant isolates were exposed to colistin alone in vitro, resistance rapidly emerged [92] . These findings highlight the potential for emergence of resistance with use of CMS/colistin monotherapy against A. baumannii. A recent report demonstrated substantially increased susceptibility of the colistin-resistant subpopulation to antibiotics that are inactive (e.g. those normally considered active only against Gram-positive bacteria) or have borderline activity against the parent colistinheteroresistant clinical isolates [89] , and this has been confirmed [93] . This unexpected finding raises the prospect of investigating rational combinations to increase colistin efficacy against A. baumannii while minimizing potential for emergence of resistance. Such an approach may be different from conventional synergy concepts; rather it may rely on colistin targeting its susceptible subpopulation, while the second antibiotic (e.g. rifampicin) targets the colistin-resistant subpopulation [89] .
Two recent clinical studies indicated that the combination of intravenous CMS and rifampicin is effective and well tolerated in severe infections caused by MDR A. baumannii [62 ,94] . In a prospective uncontrolled case series, Bassetti et al. [62 ] observed clinical and microbiological responses in 22 of 29 critically ill patients (19 nosocomial pneumonia and 10 bacteremia due to MDR A. baumannii) treated with intravenous CMS [2 million IU (160 mg CMS) three times a day] and intravenous rifampicin (10 mg/kg every 12 h). No renal failure was observed in patients with normal baseline renal function, whereas three patients who had previous renal failure developed nephrotoxicity when treated with CMS. No neurotoxicity was observed. In a retrospective study, Song et al. [94] evaluated the effectiveness and safety of the combination of CMS and rifampicin in 10 patients with VAP due to MDR A. baumannii strains (only susceptible to colistin based upon MICs). After treatment with intravenous CMS (150 mg 'colistin base activity' every 12 h, i.e. 400 mg CMS/12 h) and rifampicin (600 mg daily), seven (70%) of 10 patients benefited from the combination therapy, six of whom were cured microbiologically and one complicated by superimposed infection after clinical improvement. Although hypomagnesemia or mild hepatitis was observed in two patients, modification of the therapeutic regimen was not required and renal dysfunction did not develop during treatment. This study indicated that 7-11 days of combination therapy with CMS and rifampicin was well tolerated without serious adverse events in patients without underlying renal disease [94] .
It should be noted that, due to practical and ethical considerations, a major limitation of most clinical studies on antibiotic combinations is the lack of control groups without the combination treatment. In addition, no pharmacokinetic information is available to confirm concentrations of formed colistin and the second antibiotic at infection sites. Considering the potential for rapid development of resistance to colistin or polymyxin B [91, 92, 95] , further preclinical and clinical investigations on rational combinations with CMS/colistin are urgently required in order to increase the usefulness of this lastline antibiotic against Gram-negative 'superbugs'.
Conclusion
It is remarkable that colistin, a 50-year-old antibiotic, is increasingly being used in the 21st century for the treatment of life-threatening infections. The diversity in labeling and dosage recommendations of the pharmaceutical formulations requires urgent attention for international harmonization. Studies reported in the past 1-2 years have progressed our understanding of the pharmacokinetics and pharmacodynamics of this 'last-line' antibiotic. There is still much to be achieved, however, to allow its use to be optimized. One of the most important aspects currently being addressed is elucidation of the population pharmacokinetic, pharmacodynamic and toxicodynamic relationships that will form the basis for dosage regimen recommendations for various categories of patients. In addition, a systematic investigation of colistin combination therapies warrants greater attention as an additional means to increase efficacy while minimizing the potential for emergence of colistin resistance.
Wallace SJ, Li J, Rayner CR, et al. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008; 52:3047-3051. This study first reports the concentration-dependent stability of CMS. It has important implications for the formulation and clinical use of CMS pharmaceutical products.
